Plain-English translation of NCT05410730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called for patients with high-risk bladder cancer that hasn't invaded the muscle layer of the bladder. Researchers want to find the best dose of this medication and understand how well it works when given on its own or combined with two standard bladder cancer treatments. The trial will measure both safety and how effective the treatment is at controlling the cancer.
Currently, patients with this type of bladder cancer have limited treatment options, especially if they can't or don't want to have their bladder surgically removed. This medication is being studied to see if it offers a safer and more effective option for managing high-risk disease.
You likely qualify if…
You likely don't qualify if…
Participants will receive the new medication either alone or in combination with standard treatments like BCG (a common bladder cancer immunotherapy) or another medication called SHR-1316. The study starts with a dose-finding phase to determine the safest and most effective dose, followed by a larger phase where more patients receive that dose to confirm how well it works. You'll have regular clinic visits to receive treatment, undergo cystoscopy procedures to check your bladder, and have blood tests to monitor your safety and response to the medication.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Enrollment target
~150 participants
Started
November 2022
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenliang Wang
Shanghai Hengrui Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.